SCHEMBL7907489

SCHEMBL7907489

Nc1ncc(-c2nc(Cl)nc3c2cnn3C2CCN(C(=O)OCc3ccccc3)CC2)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 8/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
CYP2C19 P33261 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
CYP2D6 P10635 4/20 0.42
CYP2C9 P11712 4/20 0.42
CYP3A4 P08684 3/20 0.42
JAK2 O60674 2/20 0.42
PIK3CA P42336 4/20 0.41
MTOR P42345 3/20 0.41
PIK3CG P48736 1/20 0.41
MAPK14 Q16539 1/20 0.41
CSNK1G1 Q9HCP0 1/20 0.41
PIK3R1 P27986 1/20 0.40
HDAC1 Q13547 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
JAK3 P52333 1/20 0.40
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7917257 0.86 PIK3CA (0.52) PIK3CAMTORPIK3CGMAPK14CSNK1G1
SCHEMBL7907485 0.85 SMN1; SMN2 (0.50) GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A
SCHEMBL12139719 0.84 MTOR (0.53) PIK3CAMTORPIK3CG
SCHEMBL14794928 0.83 MTOR (0.52) PIK3CAMTORPIK3CG
SCHEMBL303924 0.78 GRIN2B (0.52) GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A
SCHEMBL11961137 0.74 GRIN2B (0.40) GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A
SCHEMBL3808612 0.74 GRIN2B (0.54) GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A
SCHEMBL30588167 0.74 GRIN2B (0.54) GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A
SCHEMBL26113676 0.74 GRIN2B (0.54) GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A
SCHEMBL12185939 0.73 MTOR (0.55) PIK3CAMTORPIK3CGMAPK14CSNK1G1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382207-B1 PI3K/MTOR KINASE INHIBITORS XCOVERY HOLDING CO LLC (US) 2015-04-29 EP disclosed
US-8586582-B2 PI3K/mTOR kinase inhibitors XCOVERY HOLDING COMPANY, LLC (US) 2013-11-19 US disclosed
US-8586582-B2 PI3K/mTOR kinase inhibitors XCOVERY HOLDING COMPANY, LLC (US) 2013-11-19 US disclosed
US-20110281857-A1 PI3K/MTOR KINASE INHIBITORS XCOVERY HOLDING COMPANY, LLC (US) 2011-11-17 US disclosed
US-20110281857-A1 PI3K/MTOR KINASE INHIBITORS XCOVERY HOLDING COMPANY, LLC (US) 2011-11-17 US disclosed
WO-2010056320-A2 PI3K/MTOR KINASE INHIBITORS TYROGENEX, INC. (US) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281857-A1 PI3K/MTOR KINASE INHIBITORS MTOR, PIK3CA, PI4KA GRIN2B 1356/4885SMN1; SMN2 2252/4885CYP2C19 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.